Loading...
Loading...
Celldex Therapeutics, Inc.
today reported the results of an in vitro study analyzing the
activation of human T cells with CDX-1127. CDX-1127 is a monoclonal antibody
that binds CD27 and is designed to activate patients' immune cells against
their cancer. The study further explored aspects related to both the potency
and safety profile of CDX-1127. Results were consistent with earlier work,
confirming the mechanism of action for CDX-1127 and providing additional
support for continued clinical development of the candidate. The data were
presented in a poster (#1239) entitled "Characterization of the Response of
Human T cells to an Agonist Human Anti-CD27 mAb" at the American Association
of Cancer Research (AACR) Annual Meeting in Washington DC by Tibor Keler, PhD,
Senior Vice President and Chief Scientific Officer of Celldex Therapeutics.
"The results of this study confirm that CDX-1127 elicits potent activation of
T cells by inducing their proliferation and release of important immune
modulating cytokines," said Dr. Keler. "Most importantly, we have shown that
the activation is highly regulated, which limits any safety concerns related
to non-specific stimulation of the immune system that similar candidates in
this class have faced. This finding is supported by the good safety profile
seen to date in our ongoing multi-dose Phase 1 human clinical trial. We
believe CDX-1127 is an exciting entrant to the field of immunotherapy and look
forward to presenting clinical data from planned solid tumor and hematologic
expansion cohorts from our Phase 1 study by year-end."
Study results:
This study investigated the mechanistic requirements for T cell activation by
CDX-1127 and the resulting characteristics of the activated T cells. Using
purified T cells from healthy subjects, the results of this study demonstrated
that concomitant signaling through the T Cell Receptor for antigen is required
for CDX-1127 drug activity. Therefore, widespread activation of T cells (since
the vast majority are not receiving T Cell Receptor signaling) will not be
activated by CDX-1127. Importantly, when T cells are activated through T cell
receptor stimulation and CDX-1127, they undergo multiple cell divisions,
secrete cytokines with a dominant a proinflammatory signature (IFNγ, IL-2 and
TNFα), and express activation markers consistent with an activated phenotype.
Gene expression microarray analysis revealed modulation of intracellular
signaling, protein kinases, growth and cytokine-chemokine pathways. These in
vitro characterizations will be used to guide the biomarker analysis of
subjects in the CDX-1127 Phase 1 trial to assess in vivo T cell activation. A
copy of this poster is available for viewing in the Scientific Publications
section of the Celldex website under the header "Human Monoclonal Antibody
Programs: CD27."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in